

## Successful completion of \$2.0m Share Purchase Plan

### Key Highlights

- \$2m Share Purchase Plan received strong shareholder support, with applications totalling \$2.196m
- The SPP is in addition to the successful \$12.5 million two tranche institutional Placement
- The SPP was priced at \$0.09 per ordinary share with attaching 1 for 2 options, exercisable at \$0.14, expiring two years from issue, the SPP offer closed on 6 August 2025
- Funds from the Placement and SPP will be used to drive expanded clinical adoption of Microba's core microbiome testing products.

**Microba Life Sciences Limited** (ASX: MAP) ("**Microba**" or the "**Company**"), a company at the forefront of microbiome diagnostics & therapeutics, is pleased to announce the successful completion of its fully underwritten Share Purchase Plan (**SPP**), which closed on 6 August 2025. The SPP forms part of a broader capital raising initiative, following the successful \$12.5 million institutional Placement completed in June 2025. Together, the Placement and SPP have raised approximately \$14.5 million (before costs), with funds to be directed toward driving broader clinical adoption of the Company's microbiome testing technology in key domestic and international markets.

The SPP received strong support from eligible shareholders and was oversubscribed, with valid applications totalling \$2,196,000. This amount has been scaled back to \$2,000,000, to reflect the capped SPP, and 22,222,168 New Shares and 10,944,373 New Options will be issued on Wednesday, 13 August 2025. The Company confirms that the scale back was completed in line with the scale back provisions outlined in the Share Purchase Plan Offer (**SPP Offer**) released to the ASX on 19 June 2025. New Shares issued under the SPP will rank equally with existing Microba shares from their date of issue.

### Update on the General Meeting and Placement

The New Shares and New Options under the SPP were subject to shareholder approval for the purpose of ASX Listing Rule 7.1. The Company held a general meeting of the Company on Friday, 8 August, all resolutions were passed at the General Meeting.

Following approval at the General Meeting, the 71,711,093 New Shares under the second tranche of the Placement (**Tranche 2 Placement**) and 69,444,444 New Options under both the first tranche and second tranche of the Placement will also be issued on Wednesday, 13 August 2025, being the same date as the New Shares & New Options being issued under the SPP.

### Trading Timetable

- New Shares and New Options under the SPP and Placement are expected to be issued on Wednesday, 13 August 2025
- Trading of New Shares under Tranche 2 of the Placement is expected to commence on Wednesday, 13 August 2025
- Trading of New Shares issued under the SPP is expected to commence on Thursday, 14 August 2025

*Please note that these dates are indicative only and subject to change at the Company's discretion, subject to the ASX Listing Rules and the Corporations Act.*

View this announcement on our Investor Hub: <https://ir.microba.com/link/PGqRRe>



#### JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit [ir.microba.com/welcome](https://ir.microba.com/welcome)

**Microba Life Sciences Ltd** | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621

*Not for release to U.S. wire services or distribution in the United States*

*Authorised for release by the Chair and Chief Executive Officer.*

For further information, please contact:

**Dr Luke Reid**

Chief Executive Officer

[luke.reid@microba.com](mailto:luke.reid@microba.com)

**Investor / Media Relations**

[investor@microba.com](mailto:investor@microba.com)

<https://ir.microba.com/welcome>

**About Microba Life Sciences Limited**

Microba Life Sciences is a company at the forefront of microbiome diagnostics & therapeutics and are on a mission to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit [www.microba.com](http://www.microba.com)



**JOIN MICROBA'S INTERACTIVE INVESTOR HUB**

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit [ir.microba.com/welcome](https://ir.microba.com/welcome)

**Microba Life Sciences Ltd** | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621